Synapse - Advanced Practice Providers

Results (653)

A phase I trial of CD19-targeted EGFRt/19-28z/4-1BBL armored chimeric antigen receptor (CAR) modified T cells in patients with relapsed or refractory chronic lymphocytic leukemia

Meeting Abstract

Park, J. H.; Riviere, I.; Wang, X.; Senechal, B.; Bernal, Y.; Halton, E.; Diamonte, C.; Wang, Y.; Brentjens, R. J.; Sadelain, M.
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Durable long-term survival of adult patients with relapsed B-ALL after CD19 CAR (19-28z) T-cell therapy

Meeting Abstract

Park, J. H.; Riviere, I.; Wang, X.; Senechal, B.; Wang, Y.; Mead, E.; Santomasso, B.; Halton, E.; Diamonte, C.; Bernal, Y.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL

Meeting Abstract

Park, J. H.; Santomasso, B.; Riviere, I.; Senechal, B.; Wang, X.; Purdon, T.; Wang, Y.; Halton, E.; Diamonte, C.; Li, D.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC)

Meeting Abstract

Lowery, M. A.; O'Reilly, E. M.; Harding, J. J.; Yu, K. H.; Cercek, A.; Hollywood, E.; Salehi, E.; Margona, E.; Bradley, M.; Witter, T.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Phase IB trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in patients with advanced pancreatic cancer (PC)

Meeting Abstract

Lowery, M. A.; Harding, J. J.; Yu, K. H.; Kelsen, D. P.; Bomalaski, J. S.; Glassman, D. C.; Covington, C. M.; Brenner, R.; Hollywood, E.; Barba, A.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Palliative care from cancer diagnosis for all: Memorial Sloan Kettering's "One-Two-Three" program

Meeting Abstract

Epstein, A. S.; Klimek, V. M.; Chow, K.; Desai, A. V.; Wan, P. J.; Anderson, K.; Ranghan, C.; Okpako, M.; Rawlins-Duell, R.; Kramer, D.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Neurotoxicity in patients with metastatic solid tumors treated with immune checkpoint inhibitors: A single institution retrospective analysis

Meeting Abstract

Santomasso, B.; Malani, R.; Haggiagi, A.; Holder, J.; Shames, Y.; Briggs, S.; Callahan, M.
Journal for ImmunoTherapy of Cancer (2017)

Fulltext@MSK | Save

Development and evaluation of a human single chain variable fragment (scFv) derived BCMA targeted CAR T Cell vector leads to a high objective response rate in patients with advanced MM

Meeting Abstract

Smith, E. L.; Mailankody, S.; Ghosh, A.; Masakayan, R.; Staehr, M.; Purdon, T. J.; Halton, E.; Diamonte, C.; Anant, P.; Bernal, Y.; more...
Blood (2017)

Fulltext@MSK | Save

Feasibility, tolerability, and patient-reported outcomes with pharmacokinetic (PK)-directed dosing of Evomela (propylene glycol free melphalan) for multiple myeloma and AL amyloidosis patients undergoing autologous hematopoietic stem cell transplant (AHCT)

Meeting Abstract

Shah, G. L.; Lin, A.; Schofield, R.; Sarubbi, C.; Preston, E. V.; Devlin, S. M.; Bhatt, V.; Harnicar, S. J.; Hoover, E.; Chung, D. J.; more...
Blood (2017)

Fulltext@MSK | Save

A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas

Meeting Abstract

Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
Blood (2017)

Fulltext@MSK | Save